CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 64 enrolled
Drug / intervention
Docosahexanoic Acid +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01158976
NCT01158976N/ACompleted
CompareCT.gov

Impact of Omega-3 Intake During Pregnancy on Maternal Stress and Infant Outcome

University of Chicago·interventional·Posted Jul 8, 2010·Updated May 30, 2018

In Brief

A clinical study evaluating Docosahexanoic Acid and Placebo for Healthy Pregnant Women. Completed, enrolled 64 participants across 2 sites.

Detailed Summary

This will be the first study of the effect of essential fatty acid supplementation in pregnant women living in inner-city poverty on the stress response system during pregnancy. The investigators proposed that essential fatty acid supplementation will be associated with reductions in the experience of stress, more modulated hormonal response to stress, and more optimal regulation of emotion and attention in the infant, even within the context inner-city poverty.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Pregnant Women
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 8, 2010
Enrollment StartDec 1, 2009
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.0 years ago

Interventions

Docosahexanoic Aciddietary

450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery

Placeboother

soybean oils with strawberry flavoring